Clinical Trial

A Study of HL40626S Tablets in Healthy Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.
Protocol Amendment History 2 changes
notable Sponsor changed: Highslab Therapeutics, Inc. -> HighsLab Therapeutics Inc. 2026-08-04
critical Primary endpoint(s) modified 2026-08-01
Trial Details
NCT Number NCT07736586
Lead Sponsor HighsLab Therapeutics Inc.
Conditions Psoriasis (PsO), Skin Disease, Immune System Disease, Skin Diseases, Papulosquamous
Enrollment 64 participants
Start Date 2026-08
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-03